Vitamin D Deficiency Is Associated With Retinopathy in Children and Adolescents With Type 1 Diabetes

OBJECTIVE—To examine the hypothesis that vitamin D deficiency (VDD) is associated with an increased prevalence of microvascular complications in young people with type 1 diabetes.

RESEARCH DESIGN AND METHODS—In a cross-sectional study of 517 patients, 25-hydroxyvitamin D was measured. Retinopathy was assessed by 7-field stereoscopic retinal photography, peripheral neuropathy by thermal and vibration threshold testing, and microalbuminuria by albumin excretion rate or albumin-to-creatinine ratio.

RESULTS—Retinopathy prevalence was higher in cases with VDD versus sufficiency (18 vs. 9%, P = 0.02); deficiency was not associated with microalbuminuria or neuropathy. In logistic regression, retinopathy was associated with VDD (odds ratio 2.12 [95% CI 1.03–4.33]), diabetes duration (1.13, 1.05–1.23), and HbA1c (1.24, 1.02–1.50).

CONCLUSIONS—VDD is associated with an increased prevalence of retinopathy in young people with type 1 diabetes. The inflammatory and angiogenic effects of VDD may contribute to early retinal vascular damage; however, further investigations are warranted.

Diabetes Care 34:1400–1402, 2011

Vitamin D deficiency (VDD) has been implicated in the development of diabetes complications based on studies in mice, cell cultures, and adults with diabetes (1–6). Vitamin D may confer protection via inhibition of inflammation, downregulation of the renin-angiotensin system, improved insulin secretion, and an antiproliferative effect on endothelial cells (1). In a mouse model of ischemic retinopathy, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] inhibited retinal neovascularization (5), while in cell culture it inhibited endothelial cell proliferation (6). The severity of diabetic retinopathy was inversely related to serum 1,25(OH)2D3 levels in adults with type 2 diabetes (2). However, there are no studies examining vitamin D and complications in young people. We examined the hypothesis that vitamin D deficiency is associated with microvascular complications in adolescents with type 1 diabetes.

RESEARCH DESIGN AND METHODS—This was a cross-sectional study of 517 adolescents aged 8–20 years attending the Diabetes Complications Assessment Service (DCAS) at the Children’s Hospital at Westmead, Westmead, Australia, from 2009 to 2010. The study received ethical approval from the Children’s Hospital at Westmead.

Retinopathy was assessed using 7-field stereoscopic fundal photography and defined as at least one microaneurysm or hemorrhage (7). Neuropathy in the foot was assessed by thermal threshold and vibration threshold testing (NeuroSensory TSA-II and Vibratory Sensory Analyzer; Medoc Ltd., Ramat Yishai, Israel). Presence of peripheral neuropathy was determined using published data on thermal perception testing in children and adolescents using the same equipment (8). Microalbuminuria was assessed, as previously described (7). Elevated albumin excretion rate/albumin-to-creatinine ratio (AER/ACR) was defined as AER ≥7.5 µg/min in at least 2/3 overnight urines or a mean ACR ≥1.0 mg/mmol (males) and ≥1.4 mg/mmol (females). The AER/ACR equivalent thresholds were derived from data on 7,170 adolescents with diabetes (T. Jones, Perth, Australia, personal communication).

Total 25-hydroxyvitamin D (25-OHD) was measured using the Liaison analyzer (DiaSorin Inc., Stillwater, MN). Levels were seasonally adjusted using correction factors obtained from a multiple linear regression of 550 samples from healthy children from Sydney, Australia; summer (~7.71), autumn (5.14), winter (5.03), spring (~2.46). VDD was defined as ≤50 nmol/L (9). Hemoglobin A1c (HbA1c) was measured using the Bio-Rad Diamat analyzer (Bio-Rad, Hercules, CA).

Individuals were classified as Caucasian/non-Caucasian using the Australian Bureau of Statistics (ABS) standards for classifying the ethnic and cultural composition of the Australian population (10). Socioeconomic status was determined by postcodes using the ABS Socio-Economic Indexes for Areas (10). Logistic regression was used to examine factors associated with complications (PASW, V18, IBM, Chicago, IL).

RESULTS—Vitamin D levels were performed on 495/517 (96%) patients, with mean ± SD age 14.9 ± 2.4 years, diabetes duration 7.2 ± 3.5 years, and median HbA1c 8.6 ± 1.5%. Mean ± SD 25-OHD level was 70.1 ± 23 nmol/L and 80/495 (16%) were deficient. Retinopathy was more common in young people with VDD compared with their sufficient counterparts (18 vs. 9%, P = 0.02), but there were no between-group differences for elevated AER/ACR, microalbuminuria, or peripheral nerve function. Sex, age, diabetes duration, BMI standard

From the 1School of Women’s and Children’s Health, University of New South Wales, New South Wales, Australia; the 2Institute of Endocrinology and Diabetes, Children’s Hospital at Westmead, Westmead, Australia; and the 3Discipline of Paediatrics and Child Health, University of Sydney, Sydney, Australia.

Corresponding author: Maria E. Craig, m.craig@unsw.edu.au.

Received 16 January 2011 and accepted 27 March 2011.

DOI: 10.2337/dc11-0103

© 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
deviation score (SDS), systolic blood pressure (SBP) SDS, diastolic blood pressure (DBP) SDS, HbA1c, cholesterol, insulin dose/weight, C-reactive protein, prevalence of celiac disease, and socioeconomic status also did not differ between groups. Factors associated with retinopathy, abnormal peripheral nerve function, and elevated AER/ACR are in Table 1.

**CONCLUSIONS**—This is the first study to our knowledge of young people with type 1 diabetes to demonstrate an association between VDD and diabetic retinopathy, independent of diabetes duration and HbA1c. However, VDD was not associated with abnormal peripheral nerve function or elevated AER/ACR. We speculate that the angiogenic effect of VDD contributes to retinal vascular damage, whereas renal vessels and peripheral nerves may be less susceptible.

This novel association is supported by studies of adults with type 2 diabetes and more advanced retinopathy; 1,25(OH)2D3 levels were inversely correlated with a higher grade of retinopathy (2), and lower 25-OHD levels were associated with proliferative retinopathy (3). The current finding suggests that VDD may have a permissive role in earlier stages of retinopathy.

Biological models support a causal role for VDD in proliferative retinopathy, which is characterized by neovascularization and angiogenesis. Higher serum 1,25(OH)2D3 was associated with reduced angiogenesis in both a transgenic retinoblastoma model and ischemic retinopathy in mice (5,11). This may be explained by an interaction between vitamin D and vascular endothelial growth factor (VEGF); the addition of 1,25(OH)2D3 reduced VEGF-induced proliferation in aortic endothelial cell culture (6).

The vitamin D receptor (VDR) is present in the human retina, and polymorphisms of VDR are related to retinopathy risk in type 1 diabetes. The Fok I single nucleotide polymorphism of the VDR gene was associated with increased transcriptional activity of the VDR and less severe diabetic retinopathy (12), and individuals with the TT genotype of the VDR Taq I polymorphism were less likely to have retinopathy (13). We did not examine genetic risk factors in our population; in future studies it would be valuable to examine the relationship between genes involved in vitamin D metabolism and retinopathy.

We cannot exclude the possibility that VDD is a confounder for other factors contributing to retinopathy. For example, VDD may mask the effect of ethnicity on retinopathy, given that lower vitamin D is associated with darker skin pigmentation and higher retinopathy rates are found in Hispanic, African American, and South Asian people (14). However, we found no relationship between ethnicity and retinopathy.

Because of the cross-sectional nature of this study, we cannot assume a causal relationship between VDD and retinopathy. Indeed, it is possible that VDD is a consequence of retinopathy because individuals with complications may be less mobile and have lower sun exposure. This is unlikely, however, because the study population consisted of adolescents who were otherwise well, and only early complications were detected. Although, this study is clinic-based, the individuals attending DCAS comprise approximately one-third of cases in the state of New South Wales (15).

In conclusion, this study demonstrates a novel association between VDD and retinopathy in children and adolescents with type 1 diabetes. This is supported by clinical, biological, and genetic data; however, prospective studies are required to validate this relationship and elucidate the underlying mechanisms.

**Acknowledgments**—No potential conflicts of interest relevant to this article were reported. H.K. provided statistical analysis, data interpretation, and drafting of the manuscript. K.C.D. provided data collection, statistical analysis, data interpretation, and revision of the manuscript. A.K.C. provided data collection, P.B.-A. provided statistical analysis and data interpretation. S.H. provided data collection, M.L. and J.C. provided data collection, statistical analysis, data interpretation, and revision of the manuscript. The authors thank Yoon-Hi Cho and Tracey Jolting from the Institute of Endocrinology and Diabetes, Children’s Hospital at Westmead, for assistance with data collection.

Table 1—Univariate and multivariate analysis of retinopathy, abnormal peripheral nerve function, and elevated AER or ACR in children and adolescents with type 1 diabetes

| Outcome                              | Univariate analysis | Multivariate model* | P      | OR  | 95% CI  | P      | OR  | 95% CI  | P      |
|--------------------------------------|---------------------|---------------------|--------|-----|---------|--------|-----|---------|--------|
| Retinopathy†                         |                     |                     |        |     |         |        |     |         |        |
| Vitamin D (deficient)                | 2.29                | 1.11–4.70           | 0.02   | 2.12| 1.04–4.33| 0.04   |     |         |        |
| Age                                  | 1.23                | 1.06–1.41           | 0.01   |     |         |        |     |         |        |
| Diabetes duration                    | 1.12                | 1.03–1.22           | 0.01   | 1.13| 1.05–1.23| <0.01  |     |         |        |
| HbA1c                                | 1.25                | 1.04–1.50           | 0.02   | 1.24| 1.02–1.50| 0.03   |     |         |        |
| Ethnicity (Caucasian)                | 0.63                | 0.33–1.19           | 0.15   |     |         |        |     |         |        |
| BMI SDS                              | 1.26                | 0.83–1.92           | 0.28   |     |         |        |     |         |        |
| SBP SDS                              | 1.26                | 0.87–1.80           | 0.22   |     |         |        |     |         |        |
| DBP SDS                              | 0.94                | 0.67–1.31           | 0.71   |     |         |        |     |         |        |
| Elevated AER/ACR                     | 1.04                | 0.46–2.36           | 0.92   |     |         |        |     |         |        |
| Abnormal peripheral nerve function† |                     |                     |        |     |         |        |     |         |        |
| Age                                  | 1.15                | 1.06–1.25           | <0.01  | 1.13| 1.04–1.24| 0.01   |     |         |        |
| Sex (male)                           | 1.53                | 1.03–2.28           | 0.04   | 1.60| 1.06–2.41| 0.03   |     |         |        |
| BMI SDS                              | 1.40                | 1.07–1.84           | 0.01   | 1.46| 1.11–1.92| 0.01   |     |         |        |
| SBP SDS                              | 1.33                | 1.05–1.69           | 0.02   |     |         |        |     |         |        |
| DBP SDS                              | 1.25                | 1.01–1.55           | 0.04   |     |         |        |     |         |        |
| Elevated AER/ACR                     | 1.33                | 1.02–1.73           | 0.04   | 1.34| 1.03–1.74| 0.03   |     |         |        |
| HbA1c (≥7.5)                         | 1.95                | 1.02–3.73           | 0.04   |     |         |        |     |         |        |
| Ethnicity (Caucasian)                | 0.59                | 0.37–0.94           | 0.03   | 0.59| 0.37–0.94| 0.03   |     |         |        |

*Multivariate logistic regression models for retinopathy used the subset of 495 (96%) patients that had 25-OHD levels performed. Variables with P < 0.05 in univariate analysis were included in the multivariate model. Because of significant collinearity between age and duration (P < 0.001), both variables were not included in the same model. The model containing duration was chosen because of goodness-of-fit and clinical relevance. †The 495 individuals with vitamin D levels were used in retinopathy analysis. The entire population of 917 was used in peripheral nerve function and elevated AER/ACR analysis.

References

1. Targher G, Bertolini L, Padovani R, et al. Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media
Vitamin D and retinopathy

2. Aksoy H, Akçay F, Kurtul N, Baykal O, Avci B. Serum 1,25 dihydroxy vitamin D (1,25(OH)2D3), 25 hydroxy vitamin D (25(OH)D) and parathormone levels in diabetic retinopathy. Clin Biochem 2000;33:47–51

3. Suzuki A, Kotake M, Ono Y, et al. Hypovitaminosis D in type 2 diabetes mellitus: association with microvascular complications and type of treatment. Endocr J 2006;53:503–510

4. Diaz VA, Mainous AG III, Carek PJ, Wessell AM, Everett CJ. The association of vitamin D deficiency and insufficiency with diabetic nephropathy: implications for health disparities. J Am Board Fam Med 2009;22:521–527

5. Albert DM, Scheef EA, Wang S, et al. Calcitriol is a potent inhibitor of retinal neovascularization. Invest Ophthalmol Vis Sci 2007;48:2327–2334

6. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 2000;87:214–220

7. Gallego PH, Craig ME, Hing S, Donaghue KC. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study. BMJ 2008;337:a918

8. Hilz MJ, Stemper B, Schweibold G, Neuner I, Grahmann F, Kolodny EH. Quantitative thermal perception testing in 225 children and juveniles. J Clin Neuropsychol 1998;15:529–534

9. Munns C, Zacharin MR, Rodda CP, et al.; Paediatric Endocrine Group; Paediatric Bone Australasia. Prevention and treatment of infant and childhood vitamin D deficiency in Australia and New Zealand: a consensus statement. Med J Aust 2006;185:268–272

10. Australian Bureau of Statistics. Socio-Economic Indexes for Areas (SEIFA), data cube only [Internet], 2006. Available from http://www.abs.gov.au/. Accessed 16 August 2010

11. Shokravi MT, Marcus DM, Alroy J, Egan K, Saornil MA, Albert DM. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 1995;36:83–87

12. Taverna MJ, Selam JL, Slama G. Association between a protein polymorphism in the start codon of the vitamin D receptor gene and severe diabetic retinopathy in C-peptide-negative type 1 diabetes. J Clin Endocrinol Metab 2005;90:4803–4808

13. Taverna MJ, Sola A, Guyot-Argenton C, et al. Taq I polymorphism of the vitamin D receptor and risk of severe diabetic retinopathy. Diabetologia 2002;45:436–442

14. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376:124–136

15. Taplin CE, Craig ME, Lloyd M, et al. The rising incidence of childhood type 1 diabetes in New South Wales, 1990-2002. Med J Aust 2005;183:243–246